Evaluation of galactomannan(GM) antigen in patients with rheumatoid arthritis(RA)

Wakae Tanaka,Hiroyuki Tamiya, Kunio Matsuta, Satoshi Noguchi, Masahumi Horie, Hisanao Yoshihara, Masaki Kawakami, Masaru Suzuki, Yoshio Sakamoto.

Author address: 

Respiratory Medicine, Kanto Central Hospital, Tokyo, Japan 2Respiratory Medicine, Tokyo University, Japan 3Internal Medicine, Matsuta Medical Clinic, Tokyo, Japan


Background Patients with RA are treated with anti-inflammatory and immunosuppressive drugs such as corticosteroids, disease-modifying antirheumatic drugs and tumor necrosis factor inhibitor. Therefore, they are at increased risk of life-threatening opportunistic infections including Aspergillus infection. Measurement of serum GM antigen has been reported to be useful in the early diagnosis of invasive aspergillosis (IA) in patients with haematological malignancies. Objects To evaluate the usefulness of serum GM assay for early diagnosis of Aspergillus infection in the patients with RA. Methods From January 2008 to October 2008, we collected serum samples of 346 patients with RA. GM antigen was assayed employing Platelia Aspergillus® . When GM antigen value was≥ 0.5, it was measured again between three and six months after the first measurement. Blood cell count, C-reactive protein, gamma-globulin, erythrocyte sedimentation rate and rheumatoid factor were also measured. Results Elevated GM antigen levels were demonstrated in 62 (17.9%) of 346 patients. In those patients there was a high correlation in GM antigen level between 1st and 2nd assay (r2=0.835, P

abstract No: 


Full conference title: 

20th European Respiratory Society conference
    • ERS 20th (2010)